Table 2.
Characteristics, n (%) | 2003–2004 Influenza Season | P | 2004–2005 Influenza Season | P | ||||
---|---|---|---|---|---|---|---|---|
Vaccination Status | Vaccination Status | |||||||
Full (N = 62) | Partial (N = 156) | None (N = 754) | Full (N = 287) | Partial (N = 315) | None (N = 900) | |||
Age group | .001 | <.001 | ||||||
6 to 23 months | 36 (58.1) | 107 (68.6) | 395 (52.4) | 185 (64.5) | 264 (83.8) | 416 (46.2) | ||
24 to 59 months | 26 (41.9) | 49 (31.4) | 359 (47.6) | 102 (35.5) | 51 (16.2) | 484 (53.8) | ||
Gender | .876 | .529 | ||||||
Male | 36 (58.1) | 85 (54.5) | 413 (54.8) | 163 (56.8) | 165 (52.4) | 483 (53.7) | ||
Female | 26 (41.9) | 71 (45.5) | 341 (45.2) | 124 (43.2) | 150 (47.6) | 417 (46.3) | ||
Insurance type | .007 | <.001 | ||||||
Private | 33 (53.2) | 49 (31.4) | 216 (28.7) | 153 (53.3) | 105 (33.3) | 269 (29.9) | ||
Public | 28 (45.2) | 103 (66.0) | 504 (66.8) | 130 (45.3) | 195 (61.9) | 595 (66.1) | ||
None | 1 (1.6) | 4 (2.6) | 33 (4.4) | 3 (1.1) | 14 (4.4) | 34 (3.8) | ||
Unknown | 0 (0.0) | 0 (0.0) | 1 (0.1) | 1 (0.4) | 1 (0.3) | 2 (0.2) | ||
ARI visit setting | .004 | <.001 | ||||||
Inpatient | 19 (30.7) | 21 (13.5) | 156 (20.7) | 71 (24.7) | 66 (21.0) | 192 (21.3) | ||
ED | 25 (40.3) | 59 (37.8) | 330 (43.8) | 54 (18.8) | 79 (25.1) | 288 (32.0) | ||
Outpatient | 18 (29.0) | 76 (48.7) | 268 (35.5) | 162 (56.5) | 170 (54.0) | 420 (46.7) | ||
Geographic area | <.001 | <.001 | ||||||
Cincinnati | 24 (38.7) | 49 (31.4) | 344 (45.6) | 67 (23.3) | 87 (27.6) | 321 (35.7) | ||
Nashville | 8 (12.9) | 28 (18.0) | 168 (22.3) | 105 (36.6) | 107 (34.0) | 310 (34.4) | ||
Rochester | 30 (48.4) | 79 (50.6) | 242 (32.1) | 115 (40.1) | 121 (38.4) | 269 (29.9) | ||
High-risk conditiona | <.001 | <.001 | ||||||
Yes | 29 (46.8) | 63 (40.4) | 209 (27.7) | 108 (37.6) | 82 (26.0) | 219 (24.3) | ||
No | 33 (53.2) | 93 (59.6) | 545 (72.3) | 179 (62.4) | 233 (74.0) | 681 (75.7) |
High-risk conditions included asthma, cancer, diabetes, heart disease, immune deficiency, kidney disease, sickle cell disease, cystic fibrosis, and chronic lung disease.